KR100859609B1 - 테르비나핀의 말산 부가염 - Google Patents

테르비나핀의 말산 부가염 Download PDF

Info

Publication number
KR100859609B1
KR100859609B1 KR1020037010291A KR20037010291A KR100859609B1 KR 100859609 B1 KR100859609 B1 KR 100859609B1 KR 1020037010291 A KR1020037010291 A KR 1020037010291A KR 20037010291 A KR20037010291 A KR 20037010291A KR 100859609 B1 KR100859609 B1 KR 100859609B1
Authority
KR
South Korea
Prior art keywords
terbinafine
compound
malic acid
formula
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020037010291A
Other languages
English (en)
Korean (ko)
Other versions
KR20030077606A (ko
Inventor
다니엘르 지롱
쟝-루이 레베
스테판 히르쉬
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20030077606A publication Critical patent/KR20030077606A/ko
Application granted granted Critical
Publication of KR100859609B1 publication Critical patent/KR100859609B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Seasonings (AREA)
KR1020037010291A 2001-02-07 2002-02-06 테르비나핀의 말산 부가염 Expired - Fee Related KR100859609B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0103046.9 2001-02-07
GBGB0103046.9A GB0103046D0 (en) 2001-02-07 2001-02-07 Organic Compounds
PCT/EP2002/001249 WO2002070455A1 (en) 2001-02-07 2002-02-06 Malic acid addition salts of terbinafine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020087010521A Division KR20080041756A (ko) 2001-02-07 2002-02-06 테르비나핀의 말산 부가염을 포함하는 제약 조성물

Publications (2)

Publication Number Publication Date
KR20030077606A KR20030077606A (ko) 2003-10-01
KR100859609B1 true KR100859609B1 (ko) 2008-09-23

Family

ID=9908301

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020087010521A Withdrawn KR20080041756A (ko) 2001-02-07 2002-02-06 테르비나핀의 말산 부가염을 포함하는 제약 조성물
KR1020037010291A Expired - Fee Related KR100859609B1 (ko) 2001-02-07 2002-02-06 테르비나핀의 말산 부가염

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020087010521A Withdrawn KR20080041756A (ko) 2001-02-07 2002-02-06 테르비나핀의 말산 부가염을 포함하는 제약 조성물

Country Status (27)

Country Link
US (2) US20040147603A1 (enExample)
EP (1) EP1370513B1 (enExample)
JP (1) JP4078206B2 (enExample)
KR (2) KR20080041756A (enExample)
CN (1) CN1216034C (enExample)
AT (1) ATE294154T1 (enExample)
AU (1) AU2002238534C1 (enExample)
BR (1) BR0207077A (enExample)
CA (1) CA2437592A1 (enExample)
CZ (1) CZ20032132A3 (enExample)
DE (1) DE60203890T2 (enExample)
DK (1) DK1370513T3 (enExample)
EC (1) ECSP034713A (enExample)
ES (1) ES2240698T3 (enExample)
GB (1) GB0103046D0 (enExample)
HU (1) HUP0303174A3 (enExample)
IL (2) IL157241A0 (enExample)
MX (1) MXPA03007072A (enExample)
NO (1) NO20033473L (enExample)
NZ (1) NZ527300A (enExample)
PL (1) PL204812B1 (enExample)
PT (1) PT1370513E (enExample)
RU (1) RU2289570C2 (enExample)
SI (1) SI1370513T1 (enExample)
SK (1) SK9992003A3 (enExample)
WO (1) WO2002070455A1 (enExample)
ZA (1) ZA200306029B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004004700A1 (en) * 2002-07-02 2004-01-15 Novartis Ag Methods for the treatment of sinusitis
GB0503942D0 (en) * 2005-02-25 2005-04-06 Novartis Ag Purification process
RU2286144C2 (ru) * 2004-12-02 2006-10-27 Государственное научное учреждение Институт экспериментальной ветеринарии Сибири и Дальнего Востока Сибирского отделения Россельхозакадемии (ГНУ ИЭВСиДВ СО РАСХН) Способ лечения микроспории кошек
WO2007104474A1 (en) * 2006-03-10 2007-09-20 Novartis Ag Antifungal compositions comprising (1) a salt of terbinafine with malic acid and (2) malic acid
AU2007260739A1 (en) 2006-06-14 2007-12-21 Dr. Reddy's Laboratories Limited Topical compositions
RU2350343C1 (ru) * 2007-08-13 2009-03-27 Государственное научное учреждение Институт экспериментальной ветеринарии Сибири и Дальнего Востока Сибирского отделения Россельхозакадемии (ГНУ ИЭВС и ДВ СО Россельхозакадемии) Способ лечения микроспории кошек
CA2758030C (en) 2009-01-16 2019-01-08 Exelixis, Inc. Malate salt of n-(4-{[6,7-bis(methyloxy)quin0lin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
CN106106449A (zh) * 2016-06-21 2016-11-16 广西中烟工业有限责任公司 特比萘芬制剂及其在提高烟叶角鲨烯含量中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010074748A (ko) * 1998-07-24 2001-08-09 유서홍 담즙산을 가진 청정 수용액 제형의 제조방법

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3507755A (en) * 1967-10-17 1970-04-21 Bayer Ag Process for the purification of acrylonitrile by distillation with side stream withdrawal and decantation
US4276125A (en) 1979-02-02 1981-06-30 Asahi Kasei Kogyo Kabushiki Kaisha Process for purification of crude olefinically unsaturated nitrile and condenser useful for same process
US4269667A (en) 1979-08-02 1981-05-26 Standard Oil Company Acrylonitrile purification by extractive distillation
DE19975055I1 (de) * 1979-08-22 2000-01-27 Novartis Ag Propenylamine Verfahren zu ihrer Herstellung sie enthaltende pharmazeutische Zusammensetzungen und ihre Verwending als Arzneimittel
KR850001603B1 (ko) 1980-12-03 1985-10-24 아사히 가세이 고오교오 가부시기가이샤 불포화 니트릴의 제조법
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
NZ227042A (en) * 1987-11-27 1991-05-28 Banyu Pharma Co Ltd Substituted alkylamine derivatives and pharmaceutical compositions
HU223343B1 (hu) * 1991-05-20 2004-06-28 Novartis Ag. Allil-amin-származékot tartalmazó gyógyászati készítmények és eljárás azok előállítására
US6005001A (en) * 1991-05-20 1999-12-21 Novartis Ag (Formerly Sandoz Ag) Pharmaceutical composition
HU219480B (hu) 1991-05-23 2001-04-28 Novartis Ag. Eljárás gombás körömmegbetegségek ellen helyileg alkalmazható, allil-amin-származékot tartalmazó gyógyászati készítmények előállítására
US5461068A (en) * 1993-09-29 1995-10-24 Corwood Laboratories, Inc. Imidazole derivative tincture and method of manufacture
DE4400770C1 (de) * 1994-01-13 1995-02-02 Lohmann Therapie Syst Lts Wirkstoffhaltiges Pflaster zur Abgabe von Estradiol mit mindestens einem Penetrationsverstärker, Verfahren zu seiner Herstellung und seine Verwendung
NZ280065A (en) * 1995-09-20 1998-04-27 Apotex Inc Preparation of n-alkyl-n-(1-naphthylmethyl)alk-2-en-4-ynylamine derivatives
CN1252003A (zh) 1997-03-31 2000-05-03 强生消费者公司 增强药物化合物渗透作用的溶剂系统
AU3212099A (en) 1998-03-31 1999-10-18 Johnson & Johnson Consumer Companies, Inc. Method for increasing the permeability of horny human tissue
US6231875B1 (en) 1998-03-31 2001-05-15 Johnson & Johnson Consumer Companies, Inc. Acidified composition for topical treatment of nail and skin conditions
JP2000053681A (ja) 1998-08-10 2000-02-22 Sankyo Co Ltd 三環性複素環化合物を含有する抗菌剤
US6770786B1 (en) 1999-10-22 2004-08-03 Richter Gedeon Vegyeszeti Gyar Rt. Process for preparing a substituted allylamine derivative and the salts thereof
GB0014448D0 (en) 2000-06-13 2000-08-09 Novartis Ag Organic compounds
JP4899139B2 (ja) 2000-08-10 2012-03-21 株式会社ポーラファルマ 抗真菌医薬組成物
JP4803511B2 (ja) 2000-08-25 2011-10-26 株式会社ポーラファルマ 抗真菌医薬組成物
JP2002068975A (ja) 2000-08-25 2002-03-08 Pola Chem Ind Inc 抗真菌医薬組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010074748A (ko) * 1998-07-24 2001-08-09 유서홍 담즙산을 가진 청정 수용액 제형의 제조방법

Also Published As

Publication number Publication date
PL204812B1 (pl) 2010-02-26
US20040147603A1 (en) 2004-07-29
ZA200306029B (en) 2004-06-28
HK1060876A1 (en) 2004-08-27
PT1370513E (pt) 2005-08-31
ECSP034713A (es) 2003-09-24
RU2003126176A (ru) 2005-03-10
JP4078206B2 (ja) 2008-04-23
ATE294154T1 (de) 2005-05-15
DE60203890D1 (de) 2005-06-02
WO2002070455A1 (en) 2002-09-12
HUP0303174A3 (en) 2008-03-28
US20070088084A1 (en) 2007-04-19
HUP0303174A2 (hu) 2003-12-29
KR20030077606A (ko) 2003-10-01
JP2004523567A (ja) 2004-08-05
RU2289570C2 (ru) 2006-12-20
US7488759B2 (en) 2009-02-10
DE60203890T2 (de) 2006-01-19
AU2002238534B2 (en) 2005-09-29
CZ20032132A3 (cs) 2003-10-15
KR20080041756A (ko) 2008-05-13
MXPA03007072A (es) 2003-11-18
NO20033473D0 (no) 2003-08-05
SK9992003A3 (en) 2004-01-08
DK1370513T3 (da) 2005-08-01
GB0103046D0 (en) 2001-03-21
CN1216034C (zh) 2005-08-24
BR0207077A (pt) 2004-01-20
EP1370513A1 (en) 2003-12-17
IL157241A0 (en) 2004-02-19
CA2437592A1 (en) 2002-09-12
NZ527300A (en) 2005-02-25
CN1491206A (zh) 2004-04-21
PL362554A1 (en) 2004-11-02
EP1370513B1 (en) 2005-04-27
SI1370513T1 (en) 2005-10-31
NO20033473L (no) 2003-09-17
ES2240698T3 (es) 2005-10-16
IL157241A (en) 2009-06-15
AU2002238534C1 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
US8017598B2 (en) Compositions of R(+) and S(−) pramipexole and methods of using the same
WO2015176602A1 (zh) 替诺福韦艾拉酚胺复合物及其制备方法和用途
US20180071230A1 (en) Formulations, salts and polymorphs of transnorsertraline and uses thereof
KR100859609B1 (ko) 테르비나핀의 말산 부가염
KR100525275B1 (ko) 시알산 유도체를 함유하는 고체분산체
AU2002238534A1 (en) Malic acid addition salts of terbinafine
US8022104B2 (en) Formulations of ladostigil tartrate
DK2961391T3 (en) Formulation comprising a benzothiazolone compound
HK1060876B (en) Malic acid addition salts of terbinafine
CN102770416A (zh) 美他沙酮共晶体
JP2025529301A (ja) バレニクリン関連化合物ならびにタバコ使用障害が挙げられる疾患および障害を処置するための方法
WO2017000270A1 (zh) 枸橼酸舍曲林的2种晶型及其制备方法
CN120865120A (zh) 一种利鲁唑对甲苯磺酸盐及其制备方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

A107 Divisional application of patent
AMND Amendment
J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20110917

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20110917

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000